Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide
Graham R Leggatt
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Dunn and Leggatt contributed equally to this research and share first authorship.
Search for more papers by this authorLinda A Dunn
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Current address: Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Herston, Brisbane, Australia.
Search for more papers by this authorRachel L De kluyver
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Search for more papers by this authorTrina Stewart
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Search for more papers by this authorIan H Frazer
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Search for more papers by this authorGraham R Leggatt
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Dunn and Leggatt contributed equally to this research and share first authorship.
Search for more papers by this authorLinda A Dunn
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Current address: Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Herston, Brisbane, Australia.
Search for more papers by this authorRachel L De kluyver
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Search for more papers by this authorTrina Stewart
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Search for more papers by this authorIan H Frazer
Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Search for more papers by this authorAbstract
Keratinocytes expressing the human papillomavirus (HPV) type 16 E7 protein, as a transgene driven by the K14 promoter, form a murine model of HPV-mediated epithelial cancers in humans. Our previous studies have shown that K14E7 transgenic skin grafts onto syngeneic mice are not susceptible to immune destruction despite the demonstrated presence of a strong, systemic CTL response directed against the E7 protein. Consistent with this finding, we now show that cultured, E7 transgenic keratinocytes (KC) express comparable endogenous levels of E7 protein to a range of CTL-sensitive E7-expressing cell lines but are not susceptible to CTL-mediated lysis in vitro. E7 transgenic and non-transgenic KC are susceptible to conventional mechanisms of CTL-mediated lysis, including perforin and Fas/FasL interaction when an excess of exogenous peptide is provided. The concentration of exogenous peptide required to render a cell susceptible to lysis was similar between KC and other conventional CTL targets (e.g. EL-4), despite large differences in H-2Db expression at the cell surface. Furthermore, exposure of KC to IFN-γ increased H-2Db expression, but did not substantially alter the exogenous peptide concentration required to sensitize cells for half maximal lysis. In contrast, the lytic sensitivity of transgenic KC expressing endogenous E7 is modestly improved by exposure to IFN-γ. Thus, failure of CTL to eliminate KC expressing endogenous E7, and by inference squamous tumours expressing E7, may reflect the need for a sustained, local inflammatory environment during the immune effector phase.
References
- 1Nickoloff BJ, Turka LA. Keratinocytes: key immunocytes of the integument. Am. J. Pathol. 1993; 143: 325–31.
- 2Nickoloff BJ, Turka LA. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol. Today 1994; 15: 464–9.
- 3Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 2001; 19: 47–64.
- 4Tinois E, Cobbold S, Faure M, Yeoman H, Stanley M. Cultured keratinocyte grafts are recognized, but not rejected by CD8+ T cells in vivo. Eur. J. Immunol. ?? 1989; 19: 1031–5.
- 5Cairns BA, de Serres S, Matsui M, Frelinger JA, Meyer AA. Cultured mouse keratinocyte allografts prime for accelerated second set rejection and enhanced cytotoxic lymphocyte response. Transplantation 1994; 58: 67–72.
- 6Frazer IH, Thomas R, Zhou J et al. Potential strategies utilised by papillomavirus to evade host immunity. Immunol. Rev. 1999; 168: 131–42.
- 7Borchers A, Braspenning J, Meijer J, Osen W, Gissmann L, Jochmus I, E7-specific cytotoxic T cell tolerance in HPV- transgenic mice. Arch. Virol. 1999; 144: 1539–56.
- 8Melero I, Singhal MC, McGowan P et al. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 1997; 71: 3998–4004.
- 9Doan T, Herd K, Street M et al. Human papillomavirus type 16, E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles. J. Virol. 1999; 73: 6166–4004.
- 10De Bueger MM, Van Els CA, Kempenaar J, Ponec M, Goulmy E. A new sensitive assay for measurement of cell-mediated cytotoxicity to intact layers of cultured human keratinocytes. J. Immunol. Meth. 1990; 127: 117–22.
- 11Symington FW, Santos EB. Lysis of human keratinocytes by allogeneic HLA class I-specific cytotoxic T cells. Keratinocyte ICAM-1 (CD54) and T cell LFA-1 (CD11a/CD18) mediate enhanced lysis of IFN-gamma-treated keratinocytes. J. Immunol. 1991; 146: 2169–75.
- 12Niederwieser D, Aubock J, Troppmair J et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J. Immunol. 1988; 140: 2556–64.
- 13Koelle DM, Chen HB, Gavin MA, Wald A, Kwok WW, Corey L. CD8 CTL from genital herpes simplex lesions. Recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J. Immunol. 2001; 166: 4049–58.
- 14van Els CA, de Bueger MM, Kempenaar J, Ponec M, Goulmy E. Susceptibility of human male keratinocytes to MHC-restricted H-Y-specific lysis. J. Exp Med. 1989; 170: 1469–74.
- 15Steinmuller D, Burlingham WJ. Expression of cell-defined H-Y antigen on mouse epidermal cells. Transplantation 1984; 37: 22–8.
- 16Herber R, Liem A, Pitot H, Lambert PF. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16, E7 oncogene. J. Virol. 1996; 70: 1873–81.
- 17Kagi D, Ledermann B, Burki K et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31–7.
- 18Fernando GJ, Tindle RW, Frazer IH. T-helper epitopes of the E7 transforming protein of cervical cancer associated human papillomavirus type 18 (HPV18). Virus Res. 1995; 36: 1–13.
- 19Jones SJ, Dicker AJ, Dahler AL, Saunders NA. E2F as a regulator of keratinocyte proliferation: implications for skin tumor development. J. Invest. Dermatol. 1997; 109: 187–93.
- 20Patek PQ, Collins JL, Cohn M. Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis. Nature 1978; 276: 510–11.
- 21Lin KY, Guarnieri FG, Staveley-O'Carroll KF et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996; 56: 21–6.
- 22Tindle RW, Croft S, Herd K et al. A vaccine conjugate of ‘ISCAR’ immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin. Exp. Immunol. 1995; 101: 265–71.
- 23Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16- transformed cells. Eur. J. Immunol. 1993; 23: 2242–9.
- 24Selvey LA, Dunn LA, Murray B, Tindle RW, Frazer IH. An ELISA capture assay for the E7 transforming proteins of HPV16 and HPV18. J. Virol. Meth. 1992; 37: 119–27.
- 25Frazer IH, Kluyver RD, Leggatt GR et al. Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. J. Immunol. 2001; 167: 6180–7.
- 26Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16, E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934–7.
- 27Barnard P, Payne E, McMillan NA. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology 2000; 277: 411–19.
- 28Chen L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today 1998; 19: 27–30.
- 29Petry KU, Scheffel D, Bode U et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int. J. Cancer. 1994; 57: 836–40.
- 30Frazer IH, Fernando GJ, Fowler N et al. Split tolerance to a viral antigen expressed in thymic epithelium and keratinocytes. Eur. J. Immunol. 1998; 28: 2791–800.
10.1002/(SICI)1521-4141(199809)28:09<2791::AID-IMMU2791>3.0.CO;2-B CAS PubMed Web of Science® Google Scholar
- 31Kaufmann AM, Gissmann L, Schreckenberger C, Qiao L. Cervical carcinoma cells transfected with the CD80 gene elicit a primary cytotoxic T lymphocyte response specific for HPV 16, E7 antigens. Cancer Gene Ther. 1997; 4: 377–82.
- 32Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Res. 1997; 57: 4855–61.
- 33Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997; 6: 715–26.
- 34Takeshita T, Kozlowski S, England RD et al. Role of conserved regions of class I MHC molecules in the activation of CD8+ cytotoxic T lymphocytes by peptide and purified cell-free class I molecules. Int. Immunol. 1993; 5: 1129–38.
- 35Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 1995; 375: 148–51.
- 36Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996; 4: 565–71.
- 37Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273: 104–6.
- 38Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol. 1996; 14: 207–32.
- 39Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 1997; 15: 749–95.
- 40Little MC, Gawkrodger DJ, MacNeil S. Differentiation of human keratinocytes is associated with a progressive loss of interferon gamma-induced intercellular adhesion molecule-1 expression. Br. J. Dermatol. 1996; 135: 24–31.